Arrowhead Pharmaceuticals reported early clinical data showing its experimental RNA interference drug ARO-MAPT can lower tau protein levels after subcutaneous dosing in healthy volunteers. The company said the highest dose—two injections spaced two weeks apart—reduced tau by an average of 73% after 105 days. Arrowhead positioned the results as “clinical validation” for its development platform designed to reach cells outside the liver, including in the central nervous system behind the blood-brain barrier. The study’s primary goal was safety, with secondary signals aimed at confirming target engagement and intended mechanism. The announcement lands in a crowded Alzheimer’s landscape where multiple programs have struggled to translate biomarker changes into meaningful disease modification. Arrowhead’s differentiator is the RNAi mechanism aimed at suppressing tau expression rather than focusing on amyloid clearance. However, the company still faces the core challenge for tau-directed therapies: demonstrating that tau reduction corresponds to functional benefit and slows disease progression in patient trials.